Efficacy of Autologous Bone Marrow Concentrate for Knee Osteoarthritis with and without Adipose Graft

Table 3

Baseline, follow-up, and changes in the symptomatic and functional scales for patients with available baseline and follow-up data (group A: bone marrow concentrate (BMC), group B: BMC and adipose graft, LEFS: lower extremity functional scale, NPS: numeric pain scale, SD: standard deviation, and indicates a statistically significant difference between groups).

	Group A		Group B		value
		Mean (SD)		Mean (SD)
Clinical scales
Improvement rating scale	408	46.8 (38)	166	39.3 (39.8)	0.030*
LEFS (baseline)	205	46.1 (15.8)	91	43.6 (14.9)	—
LEFS (follow-up)	205	54 (17.9)	91	53.4 (14.7)	—
NPS (baseline)	220	4 (2.3)	103	4.3 (2.0)	—
NPS (follow-up)	220	2.6 (2.3)	103	3 (2.3)	—
Changes from the baseline
Change in LEFS	205	7.9 (16.1)	91	9.8 (14.2)	0.335
Change in NPS	220	−1.4 (2.6)	103	−1.3 (2.5)	0.761
Follow-up (in months)
Improvement rating scale	408	10.4 (9.4)	166	10.7 (8.1)	—
LEFS	205	6.2 (5.0)	91	5.7 (3.8)	—
NPS	220	7 (6.6)	103	6.7 (5.3)	—